Troplasminogen alfa

Drug Profile

Troplasminogen alfa

Alternative Names: BB-10153; Tapgen; V-10153

Latest Information Update: 25 Aug 2015

Price : $50

At a glance

  • Originator Vernalis
  • Class Anti-ischaemics; Antiarrhythmics; Plasminogen activator enzymes; Thrombolytics
  • Mechanism of Action Fibrinolytic agents; Plasmin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Myocardial infarction; Stroke

Most Recent Events

  • 25 Aug 2015 Discontinued - Phase-II for Stroke in USA, Canada, Czech Republic, Denmark and Hungary (IV)
  • 12 Nov 2010 V 10153 is available for licensing in World as of 28 Feb 2000. http://www.vernalis.com/
  • 01 Aug 2005 Phase-II clinical trials in Stroke in USA, Canada, Czech Republic, Denmark and Hungary (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top